ATRA Stock Hits Five-Year Low on Goldman Bear Note

Most analysts are still extremely bullish on Atara Biotherapeutics stock

Digital Content Manager
Sep 27, 2019 at 11:54 AM
facebook twitter linkedin


The shares of drugmaker Atara Biotherapeutics Inc (NASDAQ:ATRA) are hurting today, following a scathing bear note from Goldman Sachs. The analyst downgraded the stock to "sell" from "neutral," and slashed its price target to $9 from $14 -- a roughly 34% discount to last night's close. Goldman cited Atara's lack of near-term catalysts and raised questions about the company's clinical programs -- foreseeing limited commercial opportunity for its tab-cel therapy, used to treat patients with Epstein-Barr virus.

ATRA dipped way lower earlier today, breaching recent support at the $12 region, and hitting a nearly five-year low of $11.50. Looking more broadly, the security has lost more than 60% since suffering a massive post-earnings bear gap in mid-May, and a recent attempt at a breakout was swiftly capped by the 80-day moving average. The equity has managed to recoup some of these losses at midday, though, and is now down 2.7% at $13.21.

ATRA Sept 27

Despite this recent negative price action, analysts remain quite bullish, which could lead to even more downgrades. Prior to today, ATRA held six "strong buy" ratings, compared to only two "holds." What's more, the consensus 12-month price target of $31.71 more than doubles current levels. 

While absolute options volume is light, Goldman's downgrade has lit up ATRA's options pits, with 214 puts and nearly 700 calls across the tape so far -- nine times what's typically seen at this point. The October 15 call is most active, while it looks like bears are buying to open the deep out-of-the-money December 2.50 put. 

Short sellers have been falling off the bearish bandwagon, with short interest down 4.6% in the last reporting period. The 8.5 million shares sold short still represent a solid 27.8% of the stock's float, though, and over two weeks of trading, at ATRA's average pace. Today, however, the equity has landed itself on the Short Sale Restricted (SSR) list. 
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners